Glenmede Trust’s Cymabay Therapeutics CBAY Stock Holding History

Glenmede Trust’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29,373	Closed	-$694K	–	1396
2023 Q4	$694K	Sell	29,373 -8,521	-22%	-$152K	﹤0.01%	803
2023 Q3	$565K	Buy	+37,894	New	+$502K	﹤0.01%	808
2020 Q4	–	Sell	-273	Closed	-$1K	–	2365
2020 Q3	$1K	Buy	+273	New	+$1.46K	﹤0.01%	2417

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust's CBAY Position: Q1 2024 in Review

Glenmede Trust sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 29,373 shares — an estimated $694K sold.

Glenmede Trust first reported a position in CBAY in Q3 2020 and held it in 3 quarters. The position peaked at $694K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Glenmede Trust reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Glenmede Trust sold 29,373 Cymabay Therapeutics shares in Q1 2024, an estimated $694K.
Glenmede Trust first reported a position in Cymabay Therapeutics in Q3 2020 and held it in 3 quarters.
Glenmede Trust's Cymabay Therapeutics position peaked at $694K in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Glenmede Trust's 13F filing for Q1 2024, filed 15 May 2024.